143 related articles for article (PubMed ID: 24900280)
1. Discovery of INCB8761/PF-4136309, a Potent, Selective, and Orally Bioavailable CCR2 Antagonist.
Xue CB; Wang A; Han Q; Zhang Y; Cao G; Feng H; Huang T; Zheng C; Xia M; Zhang K; Kong L; Glenn J; Anand R; Meloni D; Robinson DJ; Shao L; Storace L; Li M; Hughes RO; Devraj R; Morton PA; Rogier DJ; Covington M; Scherle P; Diamond S; Emm T; Yeleswaram S; Contel N; Vaddi K; Newton R; Hollis G; Metcalf B
ACS Med Chem Lett; 2011 Dec; 2(12):913-8. PubMed ID: 24900280
[TBL] [Abstract][Full Text] [Related]
2. Discovery of INCB3284, a Potent, Selective, and Orally Bioavailable hCCR2 Antagonist.
Xue CB; Feng H; Cao G; Huang T; Glenn J; Anand R; Meloni D; Zhang K; Kong L; Wang A; Zhang Y; Zheng C; Xia M; Chen L; Tanaka H; Han Q; Robinson DJ; Modi D; Storace L; Shao L; Sharief V; Li M; Galya LG; Covington M; Scherle P; Diamond S; Emm T; Yeleswaram S; Contel N; Vaddi K; Newton R; Hollis G; Friedman S; Metcalf B
ACS Med Chem Lett; 2011 Jun; 2(6):450-4. PubMed ID: 24900329
[TBL] [Abstract][Full Text] [Related]
3. Alkylsulfone-containing trisubstituted cyclohexanes as potent and bioavailable chemokine receptor 2 (CCR2) antagonists.
Cherney RJ; Mo R; Yang MG; Xiao Z; Zhao Q; Mandlekar S; Cvijic ME; Charo IF; Barrish JC; Decicco CP; Carter PH
Bioorg Med Chem Lett; 2014 Apr; 24(7):1843-5. PubMed ID: 24613378
[TBL] [Abstract][Full Text] [Related]
4. Discovery of INCB3344, a potent, selective and orally bioavailable antagonist of human and murine CCR2.
Xue CB; Wang A; Meloni D; Zhang K; Kong L; Feng H; Glenn J; Huang T; Zhang Y; Cao G; Anand R; Zheng C; Xia M; Han Q; Robinson DJ; Storace L; Shao L; Li M; Brodmerkel CM; Covington M; Scherle P; Diamond S; Yeleswaram S; Vaddi K; Newton R; Hollis G; Friedman S; Metcalf B
Bioorg Med Chem Lett; 2010 Dec; 20(24):7473-8. PubMed ID: 21036044
[TBL] [Abstract][Full Text] [Related]
5. Discovery of INCB10820/PF-4178903, a potent, selective, and orally bioavailable dual CCR2 and CCR5 antagonist.
Zheng C; Cao G; Xia M; Feng H; Glenn J; Anand R; Zhang K; Huang T; Wang A; Kong L; Li M; Galya L; Hughes RO; Devraj R; Morton PA; Rogier DJ; Covington M; Baribaud F; Shin N; Scherle P; Diamond S; Yeleswaram S; Vaddi K; Newton R; Hollis G; Friedman S; Metcalf B; Xue CB
Bioorg Med Chem Lett; 2011 Mar; 21(5):1442-6. PubMed ID: 21295478
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a Potent and Orally Bioavailable Dual Antagonist of CC Chemokine Receptors 2 and 5.
Carter PH; Brown GD; Cherney RJ; Batt DG; Chen J; Clark CM; Cvijic ME; Duncia JV; Ko SS; Mandlekar S; Mo R; Nelson DJ; Pang J; Rose AV; Santella JB; Tebben AJ; Traeger SC; Xu S; Zhao Q; Barrish JC
ACS Med Chem Lett; 2015 Apr; 6(4):439-44. PubMed ID: 25893046
[TBL] [Abstract][Full Text] [Related]
7. The discovery of novel cyclohexylamide CCR2 antagonists.
Lanter JC; Markotan TP; Zhang X; Subasinghe N; Kang FA; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Molloy CJ; Sui Z
Bioorg Med Chem Lett; 2011 Dec; 21(24):7496-501. PubMed ID: 22061641
[TBL] [Abstract][Full Text] [Related]
8. The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity.
Cumming JG; Bower JF; Waterson D; Faull A; Poyser PJ; Turner P; McDermott B; Campbell AD; Hudson J; James M; Winter J; Wood C
Bioorg Med Chem Lett; 2012 Jun; 22(12):3895-9. PubMed ID: 22608963
[TBL] [Abstract][Full Text] [Related]
9. Discovery of BMS-753426: A Potent Orally Bioavailable Antagonist of CC Chemokine Receptor 2.
Yang MG; Xiao Z; Zhao R; Tebben AJ; Wang B; Cherney RJ; Batt DG; Brown GD; Cvijic ME; Duncia JV; Gallela MA; Gardner DS; Khandelwal P; Malley MF; Pang J; Rose AV; Santella JB; Sarjeant AA; Xu S; Mathur A; Mandlekar S; Vuppugalla R; Zhao Q; Carter PH
ACS Med Chem Lett; 2021 Jun; 12(6):969-975. PubMed ID: 34141082
[TBL] [Abstract][Full Text] [Related]
10. Discovery of PF-5190457, a Potent, Selective, and Orally Bioavailable Ghrelin Receptor Inverse Agonist Clinical Candidate.
Bhattacharya SK; Andrews K; Beveridge R; Cameron KO; Chen C; Dunn M; Fernando D; Gao H; Hepworth D; Jackson VM; Khot V; Kong J; Kosa RE; Lapham K; Loria PM; Londregan AT; McClure KF; Orr ST; Patel J; Rose C; Saenz J; Stock IA; Storer G; VanVolkenburg M; Vrieze D; Wang G; Xiao J; Zhang Y
ACS Med Chem Lett; 2014 May; 5(5):474-9. PubMed ID: 24900864
[TBL] [Abstract][Full Text] [Related]
11. Discovery of INCB9471, a Potent, Selective, and Orally Bioavailable CCR5 Antagonist with Potent Anti-HIV-1 Activity.
Xue CB; Chen L; Cao G; Zhang K; Wang A; Meloni D; Glenn J; Anand R; Xia M; Kong L; Huang T; Feng H; Zheng C; Li M; Galya L; Zhou J; Shin N; Baribaud F; Solomon K; Scherle P; Zhao B; Diamond S; Emm T; Keller D; Contel N; Yeleswaram S; Vaddi K; Hollis G; Newton R; Friedman S; Metcalf B
ACS Med Chem Lett; 2010 Dec; 1(9):483-7. PubMed ID: 24900235
[TBL] [Abstract][Full Text] [Related]
12. Discovery of potent, orally bioavailable small-molecule inhibitors of the human CCR2 receptor.
Doyon J; Coesemans E; Boeckx S; Buntinx M; Hermans B; Van Wauwe JP; Gilissen RA; De Groot AH; Corens D; Van Lommen G
ChemMedChem; 2008 Apr; 3(4):660-9. PubMed ID: 18188859
[TBL] [Abstract][Full Text] [Related]
13. Discovery of an orally-bioavailable CC Chemokine Receptor 2 antagonist derived from an acyclic diaminoalcohol backbone.
Carter PH; Brown GD; King SR; Voss ME; Tebben AJ; Cherney RJ; Mandlekar S; Lo YC; Yang G; Miller PB; Scherle PA; Zhao Q; Decicco CP
Bioorg Med Chem Lett; 2012 May; 22(9):3311-6. PubMed ID: 22475558
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a 4-Azetidinyl-1-thiazoyl-cyclohexane CCR2 Antagonist as a Development Candidate.
Zhang X; Hou C; Hufnagel H; Singer M; Opas E; McKenney S; Johnson D; Sui Z
ACS Med Chem Lett; 2012 Dec; 3(12):1039-44. PubMed ID: 24900425
[TBL] [Abstract][Full Text] [Related]
15. Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.
Cherney RJ; Brogan JB; Mo R; Lo YC; Yang G; Miller PB; Scherle PA; Molino BF; Carter PH; Decicco CP
Bioorg Med Chem Lett; 2009 Feb; 19(3):597-601. PubMed ID: 19131247
[TBL] [Abstract][Full Text] [Related]
16. Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists.
Zhang X; Hufnagel H; Markotan T; Lanter J; Cai C; Hou C; Singer M; Opas E; McKenney S; Crysler C; Johnson D; Sui Z
Bioorg Med Chem Lett; 2011 Sep; 21(18):5577-82. PubMed ID: 21783361
[TBL] [Abstract][Full Text] [Related]
17. Small molecule antagonist of C-C chemokine receptor 1 (CCR1) reduces disc inflammation in the rabbit model.
Chou PH; Chee A; Shi P; Lin CL; Zhao Y; Zhang L; An HS
Spine J; 2020 Dec; 20(12):2025-2036. PubMed ID: 32673730
[TBL] [Abstract][Full Text] [Related]
18. Discovery and synthesis of cyclohexenyl derivatives as modulators of CC chemokine receptor 2 activity.
Brown GD; Shi Q; Delucca GV; Batt DG; Galella MA; Cvijic ME; Liu RQ; Qiu F; Zhao Q; Barrish JC; Carter PH
Bioorg Med Chem Lett; 2016 Jan; 26(2):662-666. PubMed ID: 26631321
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of 3-aminopyrrolidine derivatives as CC chemokine receptor 2 antagonists.
Lim JW; Oh Y; Kim JH; Oak MH; Na Y; Lee JO; Lee SW; Cho H; Park WK; Choi G; Kang J
Bioorg Med Chem Lett; 2010 Apr; 20(7):2099-102. PubMed ID: 20223662
[TBL] [Abstract][Full Text] [Related]
20. Discovery and SAR of PF-4693627, a potent, selective and orally bioavailable mPGES-1 inhibitor for the potential treatment of inflammation.
Arhancet GB; Walker DP; Metz S; Fobian YM; Heasley SE; Carter JS; Springer JR; Jones DE; Hayes MJ; Shaffer AF; Jerome GM; Baratta MT; Zweifel B; Moore WM; Masferrer JL; Vazquez ML
Bioorg Med Chem Lett; 2013 Feb; 23(4):1114-9. PubMed ID: 23260349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
